We narrowed to 9,027 results for: aav

#112677-AAV9

Ready-to-use AAV9 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

Sept. 8, 2020

Academic Institutions and Nonprofits only

#209655-AAV5

Ready-to-use AAV5 particles produced from pAAV.CAGFLEX.(cyto).iATPSnFR2.S29W.A95K.HaloTag (#209655). In addition to the viral particles, you will also receive purified pAAV.CAGFLEX.(cyto).iATPSnFR2.S29W.A95K.HaloTag plasmid DNA. CAG-driven, Cre-dependent expression of the high affinity ATP biosensor iATPSnFR2. These AAV preparations are suitable purity for injection into animals.

Tim Brown, HHMI-JRC Tool Translation Team

Marvin et al Proc Natl Acad Sci U S A. 2024 May 21;12

Oct. 21, 2024

Academic Institutions and Nonprofits only

#37825-AAV9-X1.1

Ready-to-use AAV9-X1.1 particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV were produced with the AAV9-X1.1 serotype, which permits efficient transduction of brain endothelial cells. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Sept. 27, 2024

Academic Institutions and Nonprofits only

#198511-AAV1

Ready-to-use AAV1 particles produced from pAAV_hSyn-DIO-PdCO-mScarlet-WPRE (#198511). In addition to the viral particles, you will also receive purified pAAV_hSyn-DIO-PdCO-mScarlet-WPRE plasmid DNA. Syn-driven Cre-dependent expression of optimized PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

Sept. 27, 2024

Academic Institutions and Nonprofits only

#84446-AAV8

Ready-to-use AAV8 particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] (#84446). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-tdTomato-ER2] plasmid DNA. CAG-driven, Cre-dependent expression of Jaws-KGC-tdTomato-ER2 for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

June 21, 2024

Academic Institutions and Nonprofits only

#59331-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-FLEX-EGFP (#59331). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-EGFP plasmid DNA. CAG-driven, Cre-dependent expression of EGFP. These AAV preparations are suitable purity for injection into animals.

Ian Wickersham

July 12, 2023

Academic Institutions and Nonprofits only

#114470-AAV2

Ready-to-use AAV2 particles produced from pAAV-Ef1a-mCherry (#114470). In addition to the viral particles, you will also receive purified pAAV-Ef1a-mCherry plasmid DNA. EF1a-driven mCherry expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Nov. 29, 2021

Academic Institutions and Nonprofits only

#114470-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-mCherry (#114470). In addition to the viral particles, you will also receive purified pAAV-Ef1a-mCherry plasmid DNA. EF1a-driven mCherry expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Sept. 15, 2021

Academic Institutions and Nonprofits only

#37825-AAV6

Ready-to-use AAV6 particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

July 16, 2025

Academic Institutions and Nonprofits only

#131002-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO mScarlet (#131002). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO mScarlet plasmid DNA. EF1a-driven, Cre-dependent mScarlet expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Sept. 27, 2024

Academic Institutions and Nonprofits only

#109048-AAV9

Ready-to-use AAV9 particles produced from pAAV-CAG-DIO-NLS-mRuby3-IRES-eGtACR1-ST (#109048). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-NLS-mRuby3-IRES-eGtACR1-ST plasmid DNA. Cre-dependent expression of the anion channelrhodopsin GtACR1 fused to ER export signal and targeted to the neuronal soma and proximal dendrites, translated from an internal ribosomal entry site (IRES) following mRuby3 expression. These AAV preparations are suitable purity for injection into animals.

Hillel Adesnik

Mardinly et al Nat Neurosci. 2018 Apr 30. pii: 10.1038/

Feb. 5, 2024

Academic Institutions and Nonprofits only

#140558-AAV9

Ready-to-use AAV9 particles produced from pAAV-hsyn-GRAB_rDA-mut (#140558). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_rDA-mut plasmid DNA. Synapsin-driven expression of control red fluorescent dopamine sensor GRAB_rDA-mut (does not respond to DA). These AAV preparations are suitable purity for injection into animals.

Yulong Li

Sun et al Nat Methods. 2020 Nov;17(11):1156-1166.

Aug. 31, 2021

Academic Institutions and Nonprofits only

#137137-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-oScarlet (#137137). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-oScarlet plasmid DNA. EF1a-driven, Cre-dependent expression of oScarlet (inhibited in presence of Flp). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 8, 2021

Academic Institutions and Nonprofits only

#45580-AAV1

Ready-to-use AAV1 particles produced from pAAV-flex-taCasp3-TEVp (#45580). In addition to the viral particles, you will also receive purified pAAV-flex-taCasp3-TEVp plasmid DNA. EF1a-driven, Cre-dependent, bicicstronic expression of designer pro-taCasp3 and TEVp. These AAV preparations are suitable purity for injection into animals.

Nirao Shah, Jim Wells

Yang et al Cell. 2013 May 9;153(4):896-909. doi: 10

Dec. 3, 2020

Academic Institutions and Nonprofits only

#69571-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-C-CreintG (#69571). In addition to the viral particles, you will also receive purified pAAV-EF1a-C-CreintG plasmid DNA. EF1a-driven expression of optimized C-terminal component of Cre recombinase dependent on GFP (Cre-DOG OPT); to be coinjected with pAAV-EF1a-N-CretrcintG (Addgene catalog# 69570) and GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Nat Neurosci. 2015 Sep;18(9):1334-41. do

Feb. 19, 2020

Academic Institutions and Nonprofits only

#69570-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-N-CretrcintG (#69570). In addition to the viral particles, you will also receive purified pAAV-EF1a-N-CretrcintG plasmid DNA. EF1a-driven expression of optimized N-terminal component of Cre recombinase dependent on GFP (Cre-DOG OPT); to be coinjected with pAAV-EF1a-C-CreintG (Addgene catalog# 69571) and GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Nat Neurosci. 2015 Sep;18(9):1334-41. do

Feb. 19, 2020

Academic Institutions and Nonprofits only